148 related articles for article (PubMed ID: 33574924)
1. A comprehensive analysis of the expression, epigenetic and genetic changes of HNF1B and ECI2 in 122 cases of high-grade serous ovarian carcinoma.
Němejcová K; Bártů M; Hojný J; Hájková N; Michálková R; Krkavcová E; Stružinská I; Bui HQ; Dundr P; Cibula D; Jirsová K
Oncol Lett; 2021 Mar; 21(3):185. PubMed ID: 33574924
[TBL] [Abstract][Full Text] [Related]
2. HNF1B, EZH2 and ECI2 in prostate carcinoma. Molecular, immunohistochemical and clinico-pathological study.
Dundr P; Bártů M; Hojný J; Michálková R; Hájková N; Stružinská I; Krkavcová E; Hadravský L; Kleissnerová L; Kopejsková J; Hiep BQ; Němejcová K; Jakša R; Čapoun O; Řezáč J; Jirsová K; Franková V
Sci Rep; 2020 Sep; 10(1):14365. PubMed ID: 32873863
[TBL] [Abstract][Full Text] [Related]
3. HNF1B expression regulates ECI2 gene expression, potentially serving a role in prostate cancer progression.
Dan C; Zhang H; Zeng W; Huang L; Gong X; Li H; Yang E; Wang L; Yao Q
Oncol Lett; 2019 Jan; 17(1):1094-1100. PubMed ID: 30655870
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer.
Shen H; Fridley BL; Song H; Lawrenson K; Cunningham JM; Ramus SJ; Cicek MS; Tyrer J; Stram D; Larson MC; Köbel M; ; Ziogas A; Zheng W; Yang HP; Wu AH; Wozniak EL; Woo YL; Winterhoff B; Wik E; Whittemore AS; Wentzensen N; Weber RP; Vitonis AF; Vincent D; Vierkant RA; Vergote I; Van Den Berg D; Van Altena AM; Tworoger SS; Thompson PJ; Tessier DC; Terry KL; Teo SH; Templeman C; Stram DO; Southey MC; Sieh W; Siddiqui N; Shvetsov YB; Shu XO; Shridhar V; Wang-Gohrke S; Severi G; Schwaab I; Salvesen HB; Rzepecka IK; Runnebaum IB; Rossing MA; Rodriguez-Rodriguez L; Risch HA; Renner SP; Poole EM; Pike MC; Phelan CM; Pelttari LM; Pejovic T; Paul J; Orlow I; Omar SZ; Olson SH; Odunsi K; Nickels S; Nevanlinna H; Ness RB; Narod SA; Nakanishi T; Moysich KB; Monteiro AN; Moes-Sosnowska J; Modugno F; Menon U; McLaughlin JR; McGuire V; Matsuo K; Adenan NA; Massuger LF; Lurie G; Lundvall L; Lubiński J; Lissowska J; Levine DA; Leminen A; Lee AW; Le ND; Lambrechts S; Lambrechts D; Kupryjanczyk J; Krakstad C; Konecny GE; Kjaer SK; Kiemeney LA; Kelemen LE; Keeney GL; Karlan BY; Karevan R; Kalli KR; Kajiyama H; Ji BT; Jensen A; Jakubowska A; Iversen E; Hosono S; Høgdall CK; Høgdall E; Hoatlin M; Hillemanns P; Heitz F; Hein R; Harter P; Halle MK; Hall P; Gronwald J; Gore M; Goodman MT; Giles GG; Gentry-Maharaj A; Garcia-Closas M; Flanagan JM; Fasching PA; Ekici AB; Edwards R; Eccles D; Easton DF; Dürst M; du Bois A; Dörk T; Doherty JA; Despierre E; Dansonka-Mieszkowska A; Cybulski C; Cramer DW; Cook LS; Chen X; Charbonneau B; Chang-Claude J; Campbell I; Butzow R; Bunker CH; Brueggmann D; Brown R; Brooks-Wilson A; Brinton LA; Bogdanova N; Block MS; Benjamin E; Beesley J; Beckmann MW; Bandera EV; Baglietto L; Bacot F; Armasu SM; Antonenkova N; Anton-Culver H; Aben KK; Liang D; Wu X; Lu K; Hildebrandt MA; ; ; Schildkraut JM; Sellers TA; Huntsman D; Berchuck A; Chenevix-Trench G; Gayther SA; Pharoah PD; Laird PW; Goode EL; Pearce CL
Nat Commun; 2013; 4():1628. PubMed ID: 23535649
[TBL] [Abstract][Full Text] [Related]
5. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
6. Analysis of expression, epigenetic, and genetic changes of HNF1B in 130 kidney tumours.
Bártů M; Hojný J; Hájková N; Michálková R; Krkavcová E; Hadravský L; Kleissnerová L; Bui QH; Stružinská I; Němejcová K; Čapoun O; Šlemendová M; Dundr P
Sci Rep; 2020 Oct; 10(1):17151. PubMed ID: 33051485
[TBL] [Abstract][Full Text] [Related]
7. [Clinicopathological study of SET subtype of ovarian high-grade serous carcinoma].
Sun YW; Shen DH; Cui SS; He HJ; Zhang XL; Wang W; Liu CR
Zhonghua Fu Chan Ke Za Zhi; 2019 Sep; 54(9):595-600. PubMed ID: 31550775
[No Abstract] [Full Text] [Related]
8. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
9. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
10. Expression, Epigenetic, and Genetic Changes of HNF1B in Colorectal Lesions: an Analysis of 145 Cases.
Bártů M; Hojný J; Hájková N; Michálková R; Krkavcová E; Simon K; Frýba V; Stružinská I; Němejcová K; Dundr P
Pathol Oncol Res; 2020 Oct; 26(4):2337-2350. PubMed ID: 32488808
[TBL] [Abstract][Full Text] [Related]
11. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma].
Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX
Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294
[No Abstract] [Full Text] [Related]
12. Next-Generation Sequencing Approach in Methylation Analysis of HNF1B and GATA4 Genes: Searching for Biomarkers in Ovarian Cancer.
Bubancova I; Kovarikova H; Laco J; Ruszova E; Dvorak O; Palicka V; Chmelarova M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28241454
[TBL] [Abstract][Full Text] [Related]
13. Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome.
Gambaro K; Quinn MC; Cáceres-Gorriti KY; Shapiro RS; Provencher D; Rahimi K; Mes-Masson AM; Tonin PN
BMC Cancer; 2015 Mar; 15():135. PubMed ID: 25886299
[TBL] [Abstract][Full Text] [Related]
14. Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma.
Zhang X; Guo G; Wang G; Zhao J; Wang B; Yu X; Ding Y
Mol Med Rep; 2015 Dec; 12(6):8021-31. PubMed ID: 26497752
[TBL] [Abstract][Full Text] [Related]
15. [Clinical significance of FOXM1 and Gli-1 protein expression in high-grade ovarian serous carcinoma].
Zhang J; Li ZY; Duan XJ; Fan XM; Liu WN; Li YH
Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):904-908. PubMed ID: 27998466
[No Abstract] [Full Text] [Related]
16. Expression, Epigenetic and Genetic Changes of HNF1B in Endometrial Lesions.
Němejcová K; Tichá I; Kleiblová P; Bártů M; Cibula D; Jirsová K; Dundr P
Pathol Oncol Res; 2016 Jul; 22(3):523-30. PubMed ID: 26685938
[TBL] [Abstract][Full Text] [Related]
17. Long Non-Coding RNA HAND2-AS1 Acts as a Tumor Suppressor in High-Grade Serous Ovarian Carcinoma.
Gokulnath P; de Cristofaro T; Manipur I; Di Palma T; Soriano AA; Guarracino MR; Zannini M
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517089
[TBL] [Abstract][Full Text] [Related]
18. Characterization of desmoglein 2 expression in ovarian serous tumors and its prognostic significance in high-grade serous carcinoma.
Chen L; Liu X; Zhang J; Liu Y; Gao A; Xu Y; Lin Y; Du Q; Zhu Z; Hu Y; Liu Y
Int J Clin Exp Pathol; 2018; 11(10):4977-4986. PubMed ID: 31949574
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
[TBL] [Abstract][Full Text] [Related]
20. HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival.
Davidson B; Holth A; Hellesylt E; Hadar R; Katz B; Tropé CG; Reich R
Hum Pathol; 2016 Feb; 48():95-101. PubMed ID: 26640230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
